Trial Profile
A P1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2020
Price :
$35
*
At a glance
- Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors Tocagen
- 18 Aug 2020 Results published in the Clinical Cancer Research
- 06 Nov 2018 Results presented in a Tocagen media release.
- 07 Aug 2018 According to a Tocagen media release, data from this study will be presented at the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology.